Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment

Changing trends in anticancer research have altered the treatment paradigm to the extent that it is difficult to investigate any anticancer drugs without mentioning immunotherapy. Thus, we are finally contemplating tumour regression using magic bullets known as immunotherapy drugs. This review explores the possible options and pitfalls in tumour regression by first elucidating the features of cancer and the importance of tumour microenvironments. Next, we evaluated the trends of anticancer therapeutics regulating tumour microenvironment. Finally, we introduced the concept of tumour regression and various targets of tumour microenvironment, which can be used in combination with current immunotherapy for tumour regression. In particular, we emphasize the importance of regulating the neurological manifestations of tumour microenvironment (N) in addition to inflammation (I) and hypoxia (H) in cancer.

• Publication year

  2019

• Venue

  Biomolecules & Therapeutics

• Publication date

  2019-11-18

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.4062/biomolther.2019.135PMID 31739382PMCID 7059813
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor

  2019cited by this paper
• Circadian Clocks and Cancer: Timekeeping Governs Cellular Metabolism.

  2019cited by this paper
• Re-education of macrophages as a therapeutic strategy in cancer.

  2019cited by this paper
• Role of Sphingosylphosphorylcholine in Tumor and Tumor Microenvironment

  2019influential reference
• Targeting Tumor Microenvironment for Cancer Therapy

  2019cited by this paper
• Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates

  2019cited by this paper
• Possible Biomarkers for Cancer Immunotherapy

  2019cited by this paper
• Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy

  2019cited by this paper
• Macrophages and Metabolism in the Tumor Microenvironment.

  2019cited by this paper
• Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

  2018cited by this paper
• Hypoxia‐inducible factor‐1 (HIF‐1) inhibitors from the last decade (2007 to 2016): A “structure–activity relationship” perspective

  2018cited by this paper
• Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs

  2018cited by this paper
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cited by this paper
• Cancer immunotherapy: challenges and clinical applications

  2018cited by this paper
• Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

  2018cited by this paper
• Updates to Clinical Information on Anticancer Immunotherapy

  2018cited by this paper
• Highly differentiated CD4 T cells Unequivocally Identify Primary Resistance and Risk of Hyperprogression to PD-L1/PD-1 Immune Checkpoint Blockade in Lung Cancer

  2018cited by this paper
• Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

  2018cited by this paper
• Cancer cell plasticity: Impact on tumor progression and therapy response.

  2018cited by this paper
• Epithelial-mesenchymal transition: Initiation by cues from chronic inflammatory tumor microenvironment and termination by anti-inflammatory compounds and specialized pro-resolving lipids.

  2018cited by this paper
• Overexpression of CD44 Standard Isoform Upregulates HIF-1α Signaling in Hypoxic Breast Cancer Cells

  2018cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC)

  2018cited by this paper
• Hypoxia Signaling and Circadian Disruption in and by Pheochromocytoma

  2018cited by this paper
• Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

  2018cited by this paper
• A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

  2018cited by this paper
• Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

  2018cited by this paper
• Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.

  2018cited by this paper
• Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs)

  2018cited by this paper
• Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

  2018cited by this paper
• Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

  2017cited by this paper
• New 2016 Data and Statistics for Global Pharmaceutical Products and Projections through 2017.

  2017cited by this paper
• Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer

  2017cited by this paper
• Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma

  2017cited by this paper
• Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.

  2017influential reference
• The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.

  2017cited by this paper
• Gut Microbiome : Its Relationship to Health and Its Modulation by Diet

  2017cited by this paper
• iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

  2017cited by this paper
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2017cited by this paper
• Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.

  2017influential reference
• Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

  2017cited by this paper
• Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

  2017cited by this paper
• Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy

  2017cited by this paper
• Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.

  2017cited by this paper
• Cancer Immunotherapy, Part 3: Challenges and Future Trends.

  2017influential reference
• Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.

  2017cited by this paper
• Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

  2017cited by this paper
• Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours

  2017cited by this paper
• Cancer Immunotherapy, Part 3: Challenges and Future Trends.

  2017cited by this paper
• Resistance to immunotherapy: clouds in a bright sky

  2017cited by this paper
• Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity

  2017cited by this paper
• Cancer Immunotherapy, Part 1: Current Strategies and Agents.

  2017influential reference
• Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation

  2017cited by this paper
• Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

  2017cited by this paper
• Cancer Immunotherapy, Part 1: Current Strategies and Agents.

  2017cited by this paper
• Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.

  2016influential reference
• Cocktails for cancer with a measure of immunotherapy

  2016cited by this paper
• Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

  2016cited by this paper
• Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

  2016cited by this paper
• Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

  2016cited by this paper
• Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

  2016cited by this paper
• Current Challenges in Cancer Treatment.

  2016influential reference
• Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

  2016cited by this paper
• Analysis of nanoparticle delivery to tumours

  2016cited by this paper
• A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment

  2016cited by this paper
• The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas

  2016cited by this paper
• The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

  2016cited by this paper
• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

  2016cited by this paper
• To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?

  2016cited by this paper
• The development of immunotherapy in older adults: New treatments, new toxicities?

  2016influential reference
• A New Era in Cancer Immunotherapy: Discovering Novel Targets and Reprogramming the Immune System

  2015cited by this paper
• Translational Implications of Tumor Heterogeneity

  2015cited by this paper
• Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

  2015cited by this paper
• Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• A top-down view of the tumor microenvironment: structure, cells and signaling

  2015cited by this paper
• Cancer immunotherapy: harnessing the immune system to battle cancer.

  2015cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• Inflammation-Induced Cell Proliferation Potentiates DNA Damage-Induced Mutations In Vivo

  2015cited by this paper
• Macrophages and cancer: from mechanisms to therapeutic implications.

  2015cited by this paper
• Inflammation and cancer: advances and new agents

  2015cited by this paper
• Sympathetic nervous system regulation of the tumour microenvironment

  2015cited by this paper
• Cancer and the Immune System: Basic Concepts and Targets for Intervention.

  2015cited by this paper
• The resolution of inflammation: Principles and challenges.

  2015cited by this paper
• Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

  2015cited by this paper
• Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C

  2015cited by this paper
• Radical Remission: Surviving Cancer Against All Odds, Kelly Turner. Publisher: HarperOne (2014), 312, ISBN 978-0-06-226875-4

  2015cited by this paper
• Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

  2015cited by this paper
• Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.

  2015cited by this paper
• A personalized view on cancer immunotherapy.

  2014cited by this paper
• HIF-1 signaling in drug resistance to chemotherapy.

  2014cited by this paper
• Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?

  2014cited by this paper
• 1070PADAPTATION OF THE IMMUNE RELATED RESPONSE CRITERIA: IRRECIST.

  2014cited by this paper
• Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC

  2014cited by this paper
• CSF-1R inhibition alters macrophage polarization and blocks glioma progression

  2013cited by this paper
• Resolvin D1 inhibits TGF-β1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32.

  2013cited by this paper
• Cancer immunotherapies, their safety and toxicity

  2013cited by this paper
• β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma

  2013cited by this paper
• Microenvironmental regulation of tumor progression and metastasis

  2013cited by this paper

• Hypoxia-induced drug-resistance bias 3D cancer spheroid drug screens.

  2026cites this paper
• Therapy-Induced Senescence (TIS) and SASP: The p53-Mediated Interplay in Cancer Progression and Treatment

  2025cites this paper
• Computational insights into marine-derived pVHL-HIF1α inhibitors: pharmacophore modelling, molecular docking, MD simulations, MM/PBSA and DFT studies

  2025cites this paper
• Evaluation of a Norcantharidin Nanoemulsion Efficacy for Treating B16F1-Induced Melanoma in a Syngeneic Murine Model

  2025cites this paper
• Y-Box Binding Protein 1: Unraveling the Multifaceted Role in Cancer Development and Therapeutic Potential

  2024cites this paper
• Unraveling the Role of Ras Homolog Enriched in Brain (Rheb1 and Rheb2): Bridging Neuronal Dynamics and Cancer Pathogenesis through Mechanistic Target of Rapamycin Signaling

  2024cites this paper
• Mitochondrial–Stem Cell Connection: Providing Additional Explanations for Understanding Cancer

  2024cites this paper
• Emerging and Promising Keywords in Biomolecules and Therapeutics for 21st Century Diseases

  2024cites this paper
• Ethacrynic Acid: A Promising Candidate for Drug Repurposing as an Anticancer Agent

  2023cites this paper
• Ethacrynic acid suppresses B7-H4 expression involved in epithelial-mesenchymal transition of lung adenocarcinoma cells via inhibiting STAT3 pathway.

  2023cites this paper
• Unraveling the Janus-Faced Role of Autophagy in Hepatocellular Carcinoma: Implications for Therapeutic Interventions

  2023cites this paper
• Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain

  2022cites this paper
• Editorial: Brain Cancers: New Perspectives and Therapies

  2022cites this paper
• Expression pattern and prognostic potential of histamine receptors in epithelial ovarian cancer

  2022cites this paper
• Suppression of Tumor Growth and Cell Migration by Indole-Based Benzenesulfonamides and Their Synergistic Effects in Combination with Doxorubicin

  2022cites this paper
• Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets

  2021cites this paper
• Role of Anillin in Tumour: From a Prognostic Biomarker to a Novel Target

  2020cites this paper
• The Role of CDK5 in Tumours and Tumour Microenvironments

  2020cites this paper
• Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments

  2020cites this paper